SEC Form 4 · accession 0001144204-16-079694
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Katherine Parker
Officer — VP of Human Resources
Period of report
Feb 4, 2016
Accepted (ET)
Feb 8, 2016 · 8:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 4, 2016 | A | 6,250 | $0.00 | A | 17,608 | D | |
| Common Stock | holding | — | — | — | 1,200 | I | By trust | |
| Common Stock | holding | — | — | — | 1,200 | I | By spouse trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $3.18 | Feb 4, 2016 | A | 37,500 | A | — | Feb 4, 2026 | Common Stock | 37,500 | 37,500 | D |
Explanation of responses
- F1Represents restricted stock units that will vest and be paid 1/4 annually over a period of 4 years beginning on February 4, 2017, in the form of one share of common stock for each restricted stock unit.
- F2Includes 391 and 587 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on June 15, 2015 and December 15, 2015, respectively.
- F3Shares subject to the option vest 1/4 annually over a period of 4 years beginning on February 4, 2017.